PMID- 21875410
OWN - NLM
STAT- MEDLINE
DCOM- 20120905
LR  - 20191027
IS  - 1875-5828 (Electronic)
IS  - 1567-2050 (Linking)
VI  - 8
IP  - 8
DP  - 2011 Dec
TI  - Influence of lithium treatment on GDNF serum and CSF concentrations in patients 
      with early Alzheimer's disease.
PG  - 853-9
AB  - Preclinical and clinical studies gave evidence that lithium could be useful in 
      the treatment of Alzheimer's disease (AD). One possible mechanism of action might 
      be the induction of neurotrophins. Recently, we found a significant increase of 
      brain-derived neurotrophic factor (BDNF) serum levels in AD patients treated with 
      lithium and a significant decrease of ADAS Cog sum scores in comparison to 
      placebo-treated patients. In another previous study we have shown that glial cell 
      line-derived neurotrophic factor (GDNF) levels in CSF of patients with early AD 
      are increased most probably due to an upregulated expression in CNS as an 
      adaptive process of the impaired brain to enhance neurotrophic support at least 
      in early stages of disease. Here we assessed the influence of a lithium treatment 
      on GDNF serum and cerebrospinal fluid (CSF) concentrations in a subset of a 
      greater sample recruited for a randomized, single-blinded, placebo-controlled, 
      parallel-group multicenter 10-week study, investigating the efficacy of lithium 
      treatment in AD patients. We found a significant negative correlation of lithium 
      concentration in serum with GDNF concentration in CSF at the end of treatment (r 
      = -0.585, p = 0.036) and with the difference of GDNF concentration in CSF before 
      and after treatment (r = - 0.755, p = 0.003). However, we could not show a 
      difference in GDNF concentrations between the patients after the treatment with 
      lithium or placebo (serum, mean +/- standard deviation: 434.3 +/- 117.9 pg/ml versus 
      543.8 +/- 250.0 pg/ml, p = 0.178; CSF, 62.3 +/- 37.4 pg/ml versus 72.8 +/- 43.9 pg/ml, 
      p = 0.511). The findings of the present investigation indicated that beneficial 
      effects of the lithium treatment might reduce the necessity of enhanced GDNF 
      expression in the CNS in early AD.
FAU - Straten, Guido
AU  - Straten G
AD  - Depatment of Anesthesiology and Intensive Care, University of Tubingen, Germany.
FAU - Saur, Ralf
AU  - Saur R
FAU - Laske, Christoph
AU  - Laske C
FAU - Gasser, Thomas
AU  - Gasser T
FAU - Annas, Peter
AU  - Annas P
FAU - Basun, Hans
AU  - Basun H
FAU - Leyhe, Thomas
AU  - Leyhe T
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Curr Alzheimer Res
JT  - Current Alzheimer research
JID - 101208441
RN  - 0 (Antimanic Agents)
RN  - 0 (Glial Cell Line-Derived Neurotrophic Factor)
RN  - 0 (Lithium Compounds)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Sulfates)
RN  - 919XA137JK (lithium sulfate)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/blood/cerebrospinal fluid/*drug therapy
MH  - Antimanic Agents/pharmacology/therapeutic use
MH  - Cognitive Dysfunction/blood/cerebrospinal fluid/*drug therapy
MH  - Female
MH  - Glial Cell Line-Derived Neurotrophic Factor/*blood/*cerebrospinal fluid
MH  - Humans
MH  - Lithium Compounds/*pharmacology
MH  - Male
MH  - Middle Aged
MH  - Neuroprotective Agents/pharmacology/therapeutic use
MH  - Neuropsychological Tests
MH  - Single-Blind Method
MH  - Sulfates/*pharmacology
EDAT- 2011/08/31 06:00
MHDA- 2012/09/06 06:00
CRDT- 2011/08/31 06:00
PHST- 2010/08/30 00:00 [received]
PHST- 2011/05/14 00:00 [revised]
PHST- 2011/05/17 00:00 [accepted]
PHST- 2011/08/31 06:00 [entrez]
PHST- 2011/08/31 06:00 [pubmed]
PHST- 2012/09/06 06:00 [medline]
AID - BSP/CAR /0208 [pii]
AID - 10.2174/156720511798192754 [doi]
PST - ppublish
SO  - Curr Alzheimer Res. 2011 Dec;8(8):853-9. doi: 10.2174/156720511798192754.